Short-Term Hypolipidemic Effects of Pravastatin in Patients with Hyperlipidemia.
10.4070/kcj.1992.22.1.140
- Author:
Jong Hoa BAE
;
Heung Sun KANG
;
Kwon Sam KIM
;
Myung Shick KIM
;
Jung Sang SONG
- Publication Type:Original Article
- Keywords:
Pravastatin;
Hyperlipidemia
- MeSH:
Atherosclerosis;
Cholesterol;
Coronary Artery Disease;
Coronary Vessels;
Diet Therapy;
Female;
Humans;
Hydroxymethylglutaryl-CoA Reductase Inhibitors;
Hyperlipidemias*;
Incidence;
Male;
Plasma;
Pravastatin*;
Risk Factors;
Triglycerides
- From:Korean Circulation Journal
1992;22(1):140-145
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND: Hyperlipidemia is the one of the major risk factors causing the atherosclerosis of coronary arteries. Treatment of hyperlipidemia with drugs has been confirmed the effects of therapy showing a decreased incidence of coronary artery disease. Pravastatin is one of the new HMG-CoA reductase inhibitors and we studied the short-term hypolipidemic effects and safety of pravastatin in patients with hyperlipidemia. METHODS: We studied 31 patients(7 males and 24 females ; range of age, 36-67 years) for 12 weeks whose plasma levels of total cholesterol were higher than 250mg% after one month period of diet therapy. Pravastatin was administered 10mg/day and measured lipid profiles at 4 week interval. RESULTS: Pravastatin reduced the plasma total cholesterol from 286.2mg% to 212.3mg% (25.9%), the LDL-cholesterol from 204.2mg% to 143.6mg% (29.7%), the triglyceride from 226.0mg% to 161.4mg% (28.6%) after 12 weeks treatment. The HDL-cholesterol increased from 25.8mg% to 46.4mg% (20.5%) after pravastatin therapy. These changes were disclosed all statistically significant compared to baseline levels(p<0.01). The clinical and laboratory examinations before and after pravastatin treatment showed no particular abnormal findings. CONCLUSIONS: These results suggested that short-term pravastatin therapy in patients with hyperlipidemia seems to be very effective and safe.
